Valuation: Genelux Corporation

Market Cap 131M 116M 107M 98.78M 185M 12.73B 189M 1.28B 501M 6.21B 493M 483M 21.54B P/E 2026 *
-3.61x
P/E 2027 * -3.96x
Enterprise Value 131M 116M 107M 98.78M 185M 12.73B 189M 1.28B 501M 6.21B 493M 483M 21.54B EV / Sales 2026 *
-
EV / Sales 2027 * 10.8x
Free-Float
86.05%
Yield 2026 *
-
Yield 2027 * -
1 day+0.68%
1 week+5.67%
Current month-1.00%
1 month+2.05%
3 months+18.25%
6 months+3.83%
Current year-31.65%
1 week 2.78
Extreme 2.775
3
1 month 2.78
Extreme 2.775
3.18
Current year 2.29
Extreme 2.29
4.99
1 year 2.29
Extreme 2.29
8.54
3 years 1.6
Extreme 1.6
30.44
5 years 1.6
Extreme 1.6
40.98
10 years 1.6
Extreme 1.6
40.98
Manager TitleAgeSince
Chief Executive Officer 67 28/05/2014
Director of Finance/CFO 42 30/01/2025
Chief Tech/Sci/R&D Officer 55 01/05/2026
Director TitleAgeSince
Chairman 73 01/01/2014
Director/Board Member 68 01/09/2002
Director/Board Member 73 11/09/2023
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Sell

Director

-12,000 0.0268%
16/06/26 Free

Director

59,975 0.1338%
16/06/26 Free

Chief Executive Officer

730,601 1.6293%
Change 5-day change 1-year change 3-year change Capi.($)
+0.68%+5.67%-17.22%-85.30% 131M
+1.23%-3.08%+53.96%+87.98% 55.27B
+5.09%+6.24%+63.15%+66.42% 54.15B
+0.74%-0.22%+3.66%+424.07% 23.11B
+0.35%+0.46%-19.74%-14.06% 23.22B
+1.03%-0.76%+40.14%-3.59% 20.33B
-0.37%+0.71%+31.36%-29.32% 17.91B
+0.87%-2.80%+37.96%+600.00% 15.76B
-2.54%-12.88%+168.62%+289.45% 15B
+0.97%-0.29%+22.29%+179.14% 13.82B
Average +0.81%-0.16%+38.42%+151.48% 23.87B
Weighted average by Cap. +1.56%+1.19%+45.41%+140.76%

Financials

2026 *2027 *
Net sales - 12.18M 10.71M 9.95M 9.15M 17.17M 1.18B 17.48M 119M 46.42M 575M 45.73M 44.74M 2B
Net income -37.1M -32.63M -30.31M -27.88M -52.28M -3.59B -53.22M -362M -141M -1.75B -139M -136M -6.08B -37.87M -33.3M -30.94M -28.46M -53.36M -3.67B -54.32M -370M -144M -1.79B -142M -139M -6.21B
Net Debt - -
Logo Genelux Corporation
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Employees
26
Date Price Change Volume
23/07/26 $2.980 +0.68% 123,860
22/07/26 $2.960 +2.42% 108,167
21/07/26 $2.890 -1.37% 60,964
20/07/26 $2.930 +2.09% 165,686
17/07/26 $2.870 +1.77% 77,177
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
2.960USD
Average target price
17.50USD
Spread / Average Target
+491.22%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GNLX Stock